N/A N=49 Treatment of Androgenetic Alopecia in Males
Androgenetic Alopecia · Hair Loss · Male Pattern Baldness
Primary: Changes in Terminal Hair Count at 16 and 26 Weeks Over Baseline — 17.7; 2.8; 18.4; 1.6 change in terminal hair count
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=300 Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Androgenetic Alopecia · Coronavirus Disease 2019 · Covid19
Primary: Androgenetic Alopecia Frequency in Participants. — 209; 37; 11; 43 Participants
Phase 2 N=31 A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Androgenetic Alopecia
Primary: Mean Change From Baseline in Target Area Hair Count (TAHC) — 8.6 hairs/cm^2
N/A N=79 Treatment of Androgenic Alopecia in Males
Androgenetic Alopecia · Hair Loss · Male Pattern Baldness
Primary: Changes in Terminal Hair Count at 16 and 26 Weeks Compared to Baseline in Men Diagnosed With Androgenetic Alopecia — 23.5; 20.4; 4.4; 25.7 hairs per cm^2
N/A N=72 Treatment of Androgenetic Alopecia in Females, 9 Beam
Androgenetic Alopecia · Hair Loss · Female Pattern Baldness
Primary: Changes in Terminal Hair Count Week 16 and 26 Weeks Over Baseline — 1.3; 14.8; 2.8; 20.2 hairs per cm^2
Phase 2 N=71 Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
Alopecia, Androgenetic
Primary: Non-vellus Target Area Hair Count (TAHC) — 20.3; 22.4; 14.0 hair count
N/A N=63 Treatment of Androgenetic Alopecia in Females, 12 Beam
Androgenetic Alopecia · Hair Loss · Female Pattern Baldness
Primary: Change in Hair Count at 16 and 26 Weeks Over Baseline — -0.8; 12.5; 3.0; 20.6 hairs per cm^2
Phase 2 N=244 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
Alopecia · Alopecia, Androgenetic · Baldness
Primary: Change From Baseline in Target Area Hair Count (TAHC) — 131.3; 140.4; 129.0; 9.3 terminal hairs/cm2
Phase 3 N=120 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
Alopecia
Primary: Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs) — 64; 2 Participants
N/A N=63 Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia
Male Pattern of Hair Loss, Androgenic Alopecia
Primary: Change From Baseline in Investigator's Rating of Standardized Global Photographs at Week 12 — 5.0; 5.1; 5.1; 5.1 Score on a scale
N/A N=61 Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia
Female Pattern Hair Loss, Androgenic Alopecia
Primary: Change From Baseline in Investigator's Rating of Global Photographs at Week 12 — 4.9; 4.9; 4.8; 5.0 Score on a scale
Phase 2 N=169 A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
Alopecia
Primary: Change From Baseline in Target Area Hair Count (TAHC) at Week 24 — 6.7; 7.1 terminal hairs/cm^2 — p=0.9239
Phase 3 N=458 Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia
Alopecia, Androgenetic
Primary: Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24 — 20.2; 6.7; 21.1 Hairs — p=<.001
Phase 3 N=153 A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia
Alopecia
Primary: Change From Baseline Hair Growth Assessed by Macrophotographic Technique (Hair Count) in the Vertex at 6 Months. — 148.14; 144.27; 162.27; 149.57 hair count per…
Phase 3 N=24 Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%
Androgenetic Alopecia
Primary: Change in Hair Diameter — 57.42; 51.58; 60.92; 51.17 micrometer
N/A N=71 STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
Alopecia, Androgenetic
Primary: Safety & Tolerability Assessment of SAE/AE — 5; 9; 12; 2 events
N/A N=20 Efficacy Study of a Cosmetic Lotion in the Treatment of Androgenetic Alopecia in Males and Females
Androgenetic Alopecia
Primary: Change of the Amount of Hair Loss in a Pull Test — 2.75 Fallen hair
Phase 3 N=917 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
Androgenetic Alopecia
Primary: Change From Baseline (BL) in Target Area Hair Count (HC) Within a 2.54 Centimeter (cm) (1 Inch) Diameter Circle at the Vertex at Week 24, as Assessed by…
Phase 2 N=307 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
Alopecia · Alopecia, Androgenetic · Baldness
Primary: Change From Baseline in Target Area Hair Count (TAHC) — 135.0; 145.7; 151.5; 143.7 terminal hairs/cm^2
N/A N=44 A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
Androgenetic Alopecia
Primary: Percentage Increase in Terminal Hair Counts From Pre-Treatment, Baseline for Active Test Subjects Over the Placebo Test Subjects. — 12.48; 63.67 percent change — p=<0.001
Phase 3 N=117 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Alopecia
Primary: Number of Participants With Adverse Events (AE) Related to Sexual Function in the Double-blind Treatment Period — 5; 9 Participants — p=0.27
N/A N=8 Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling
Androgenic Alopecia
Primary: Total Area Hair Count — 126.8 hairs per cm^2
Phase 2 N=9 Topical Bimatoprost Effect on Androgen Dependent Hair Follicles
Male Pattern Hair Loss · Androgenetic Alopecia
Primary: Percent Change in Target Area Total Hair Count — -2.6; 27.4; 4.9; -5.8 percentage change in total hair count
Phase 2 N=87 ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
Alopecia
Primary: Percent Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -25.6; -30.4; -25.9; -6.3 percent — p=0.011
N/A N=7 Adipose-derived SVF for Treatment of Alopecia
Androgenetic Alopecia
Primary: Incidence of Treatment-emergent Adverse Events (Safety) — 0 adverse events
N/A N=160 Modulated Light Therapy in Participants With Pattern Hair Loss
Androgenetic Alopecia
Primary: Mean Change in Terminal Hair Count From Baseline to 16 Weeks — -15.53; 14.26; 18.94; 5.22 Change in total hair counts
Phase 3 N=322 Clinical Trial in Females With Female Pattern Hair Loss
Alopecia
Primary: Target Area Hair Count (TAHC) — 167.3; 169.7; 192.8; 194.4 hairs per centimeter squared — p=0.9170
Phase 3 N=718 PF-06651600 for the Treatment of Alopecia Areata
Alopecia Areata
Primary: Percentage of Participants With an Absolute Severity of Alopecia Tool (SALT) Score of Less Than or Equal to 20 at Week 24 — 30.65; 22.31; 23.39; 14.29 Percentage of…
Phase 2 N=20 Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women
Alopecia
Primary: Change in Hair Count — 7.7; 22.7 percent change — p=.009
Phase 2 N=60 Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Alopecia Areata
Primary: Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 — -6.3; 2.3 score on a scale